INBRX-109 + 5-fluorouracil + irinotecan

INBRX-109 + 5-fluorouracil + irinotecan is a **combination therapy** involving a recombinant, humanized tetravalent monoclonal antibody (INBRX-109) that targets death receptor 5 (DR5), together with two chemotherapeutic agents, **5-fluorouracil** and **irinotecan**. INBRX-109 acts as a DR5 agonist, inducing apoptosis in cancer cells via clustering of DR5, leading to activation of caspase-8 and downstream executioner caspases-3 and -7. 5-fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and RNA/DNA synthesis; irinotecan is a topoisomerase I inhibitor that promotes DNA damage and cell death. The combination is under investigation in **solid tumors including sarcomas and colorectal adenocarcinoma**. INBRX-109 is developed by Inhibrx and marketed as ozekibart for clinical trials[1][2][3][4][5][6].

Brand names

ozekibart

Other names

INBRX-109 + 5-fluorouracil + irinotecan